Left ventricular systolic dysfunction predicted by artificial intelligence using the electrocardiogram in Chagas disease patients-The SaMi-Trop cohort

Imagem de Miniatura
Arquivos
art_BRITO_Left_ventricular_systolic_dysfunction_predicted_by_artificial_intelligence_2021.PDF (2.35 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
BRITO, Bruno Oliveira de Figueiredo
ATTIA, Zachi I.
MARTINS, Larissa Natany A.
PEREL, Pablo
NUNES, Maria Carmo P.
CARDOSO, Clareci Silva
FERREIRA, Ariela Mota
GOMES, Paulo R.
RIBEIRO, Antonio Luiz Pinho
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.15, n.12, article ID e0009974, 16p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundLeft ventricular systolic dysfunction (LVSD) in Chagas disease (ChD) is relatively common and its treatment using low-cost drugs can improve symptoms and reduce mortality. Recently, an artificial intelligence (AI)-enabled ECG algorithm showed excellent accuracy to detect LVSD in a general population, but its accuracy in ChD has not been tested. ObjectiveTo analyze the ability of AI to recognize LVSD in patients with ChD, defined as a left ventricular ejection fraction determined by the Echocardiogram <= 40%. Methodology/principal findingsThis is a cross-sectional study of ECG obtained from a large cohort of patients with ChD named Sao Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) Study. The digital ECGs of the participants were submitted to the analysis of the trained machine to detect LVSD. The diagnostic performance of the AI-enabled ECG to detect LVSD was tested using an echocardiogram as the gold standard to detect LVSD, defined as an ejection fraction <40%. The model was enriched with NT-proBNP plasma levels, male sex, and QRS >= 120ms.Among the 1,304 participants of this study, 67% were women, median age of 60; there were 93 (7.1%) individuals with LVSD. Most patients had major ECG abnormalities (59.5%). The AI algorithm identified LVSD among ChD patients with an odds ratio of 63.3 (95% CI 32.3-128.9), a sensitivity of 73%, a specificity of 83%, an overall accuracy of 83%, and a negative predictive value of 97%; the AUC was 0.839. The model adjusted for the male sex and QRS >= 120ms improved the AUC to 0.859. The model adjusted for the male sex and elevated NT-proBNP had a higher accuracy of 0.89 and an AUC of 0.874. ConclusionThe AI analysis of the ECG of Chagas disease patients can be transformed into a powerful tool for the recognition of LVSD. Author summaryChagas disease (ChD) is caused by the protozoan parasite Trypanosoma cruzi and continues to be a health problem despite the control of its transmission. ChD is a heterogeneous condition with a wide variation in its clinical course and prognosis. The majority (60%-70%) of infected individuals remain asymptomatic throughout life. Although some develop only conduction defects and mild segmental wall motion abnormalities, others develop severe symptoms of heart failure (HF), thromboembolic phenomena, and life threatening ventricular arrhythmias. HF is one of major causes of the death of patients with ChD. There is some evidence on effective drugs against the parasite in the chronic form of the disease capable of preventing long-term adverse outcomes, but it is still limited. However low-cost medications are able to reduce mortality and improve the quality of life of patients with HF. Because of the lack of tertiary care facilities outside urban centers, an automatic diagnostic tool based on the ECG, which is a relatively simple exam without requiring human interpretation, would improve the capacity to recognize HF. Recently, digital signals of the electrocardiogram were recognized by Artificial Intelligence (AI) and associated with an excellent accuracy for HF in the general population. Our results demonstrate that AI-ECG could ensure a rapid recognition of HF in patients who require a referral to a cardiologist and the use of disease-modifying drugs. AI can be used as a powerful public heath tool, it can transform the lives of 6 million patients with ChD worldwide, and it may well have a formidable impact on patient management and prognosis.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/44453
Referências
  1. Acquatella H, 2018, J AM SOC ECHOCARDIOG, V31, P3, DOI 10.1016/j.echo.2017.10.019
  2. Attia ZI, 2019, NAT MED, V25, P70, DOI 10.1038/s41591-018-0240-2
  3. Botoni FA, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2006.12.017
  4. Cardoso CS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011181
  5. CHAGAS Carlos, 1922, Memorias do Instituto Oswaldo Cruz, V14, P5, DOI 10.1590/S0074-02761922000100001
  6. Brito BOD, 2018, J ELECTROCARDIOL, V51, P1039, DOI 10.1016/j.jelectrocard.2018.08.031
  7. Brito BOD, 2018, REV SOC BRAS MED TRO, V51, P570, DOI 10.1590/0037-8682-0184-2018
  8. Diamantino AC, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13686
  9. Echeverria LE, 2020, GLOB HEART, V15, DOI 10.5334/gh.484
  10. HW. PRCRB, 1982, MINNESOTA CODE MANUA
  11. Liu CY, 2017, J AM COLL CARDIOL, V70, P3102, DOI 10.1016/j.jacc.2017.10.044
  12. Maisel A, 2008, EUR J HEART FAIL, V10, P824, DOI 10.1016/j.ejheart.2008.07.014
  13. Minchole A, 2019, NAT MED, V25, P22, DOI 10.1038/s41591-018-0306-1
  14. Moraes DN, 2018, AM J CARDIOL, V121, P364, DOI 10.1016/j.amjcard.2017.10.020
  15. Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
  16. Nadruz W, 2018, HEART, V104, P1522, DOI 10.1136/heartjnl-2017-312869
  17. Nascimento BR, 2012, J ELECTROCARDIOL, V45, P43, DOI 10.1016/j.jelectrocard.2011.04.011
  18. Oliveira CD, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014176
  19. Nunes MCP, 2018, CIRCULATION, V138, pE169, DOI 10.1161/CIR.0000000000000599
  20. Nunes MCP, 2013, J AM COLL CARDIOL, V62, P767, DOI 10.1016/j.jacc.2013.05.046
  21. Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
  22. Rassi A, 2006, NEW ENGL J MED, V355, P799, DOI 10.1056/NEJMoa053241
  23. Ribeiro ALP, 2006, INT J CARDIOL, V109, P34, DOI 10.1016/j.ijcard.2005.05.048
  24. Ribeiro ALP, 2002, LANCET, V360, P461, DOI 10.1016/S0140-6736(02)09638-1
  25. Ribeiro ALP, 2000, PACE, V23, P2014
  26. Ribeiro AL, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002078
  27. Ribeiro AL, 2012, NAT REV CARDIOL, V9, P576, DOI 10.1038/nrcardio.2012.109
  28. Ribeiro ALP, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000632
  29. Salles G, 2003, CIRCULATION, V108, P305, DOI 10.1161/01.CIR.0000079174.13444.9C
  30. Shen L, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.117.004361
  31. Thygesen K, 2018, GLOB HEART, V13, P305, DOI [10.1016/j.jacc.2018.08.1038, 10.1093/eurheartj/ehy462]
  32. Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - ODS/03